

Sridharan Gururangan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7329754/publications.pdf>

Version: 2024-02-01

40
papers

3,324
citations

331670

21
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

4853
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
2	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	1.2	9
3	MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Neuro-Oncology</i> , 2022, 24, i123-i124.	1.2	0
4	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
5	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
6	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
7	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	7.7	65
8	IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). <i>Neuro-Oncology</i> , 2020, 22, iii361-iii361.	1.2	0
9	IMMU-26. DISEASE CONTROL IN A PEDIATRIC PATIENT WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) AND SOMATIC HIGH MICROSATELLITE INSTABILITY (MSI-H) WITH PD-1 INHIBITOR NIVOLUMAB (NIVO) ONLY AND NO FOCAL RADIOTHERAPY (RT). <i>Neuro-Oncology</i> , 2020, 22, iii365-iii365.	1.2	0
10	Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 179-184.	1.6	2
11	EMBR-14. RECLASSIFICATION OF CENTRAL NERVOUS SYSTEM PRIMITIVE NEUROECTODERMAL TUMOR (CNS-PNET) INTO ENTITIES REFLECTS OUTCOME: RESULTS FROM THE PROSPECTIVE SJYC07 AND SJMB03 TRIALS. <i>Neuro-Oncology</i> , 2018, 20, i71-i72.	1.2	0
12	EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS. <i>Neuro-Oncology</i> , 2018, 20, i71-i71.	1.2	0
13	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	1.2	236
14	Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1589-1595.	4.2	15
15	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 148-160.	2.4	38
16	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
17	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1855-1858.	1.5	6
18	Childhood medulloblastoma: current and future treatment strategies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1299-1317.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€™Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	1.6	368
20	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 47-53.	0.8	14
21	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomasâ€™a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2014, 16, 310-317.	1.2	132
22	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10065-10065.	1.6	10
23	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
24	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2035-2035.	1.6	8
25	Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymomaâ€“a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2012, 14, 1404-1412.	1.2	50
26	Novel mutations target distinct subgroups of medulloblastoma. <i>Nature</i> , 2012, 488, 43-48.	27.8	742
27	Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3069-3075.	1.6	178
28	Additional Evidence of a Nonverbal Learning Disability in Survivors of Pediatric Brain Tumors. <i>Children's Health Care</i> , 2009, 38, 49-63.	0.9	15
29	Late Effects of Chemotherapy. <i>Cancer Treatment and Research</i> , 2009, 150, 43-65.	0.5	9
30	Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. <i>Neuro-Oncology</i> , 2008, 10, 745-751.	1.2	61
31	Phase I Trial of VNP40101M (Clotetazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2008, 14, 1124-1130.	7.0	20
32	Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. <i>Neuro-Oncology</i> , 2008, 10, 93-97.	1.2	21
33	Temozolomide in Children with progressive low-grade glioma1. <i>Neuro-Oncology</i> , 2007, 9, 161-168.	1.2	127
34	Advances in the diagnosis and treatment of malignant childhood brain tumors. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 120-2.	0.3	0
35	Incidence and patterns of neuraxis metastases in children with diffuse pontine gliomaâ€™.... <i>Journal of Neuro-Oncology</i> , 2006, 77, 207-212.	2.9	68
36	Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). <i>Clinical Cancer Research</i> , 2006, 12, 1540-1546.	7.0	37

#	ARTICLE	IF	CITATIONS
37	[18F]Fluorodeoxyglucose-Positron Emission Tomography in Patients with Medulloblastoma. <i>Neurosurgery</i> , 2004, 55, 1280-1289.	1.1	39
38	High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas. <i>Journal of Clinical Oncology</i> , 2003, 21, 2187-2191.	1.6	110
39	Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 2951-2958.	1.6	105
40	Innovations in design and delivery of chemotherapy for brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 583-597.	1.0	37